Dymista^®^ “can be considered the drug of choice”^1^ |For moderate/severe allergic rhinitis in patients 12 and over|
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to MEDA:email@example.com
1. Leung et al. MP29-02: A major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5): 1216.